Addiction - Pipeline Review, H2 2015

Date: December 30, 2015
Pages: 369
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A22C7638456EN
Leaflet:

Download PDF Leaflet

Addiction - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Addiction - Pipeline Review, H2 2015’, provides an overview of the Addiction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Addiction
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Addiction and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Addiction pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Addiction
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Addiction Overview
Therapeutics Development
Pipeline Products for Addiction - Overview
Pipeline Products for Addiction - Comparative Analysis
Addiction - Therapeutics under Development by Companies
Addiction - Therapeutics under Investigation by Universities/Institutes
Addiction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Addiction - Products under Development by Companies
Addiction - Products under Investigation by Universities/Institutes
Addiction - Companies Involved in Therapeutics Development
AbbVie Inc.
Addex Therapeutics Ltd
Adial Pharmaceuticals, LLC
Aelis Farma S.A.S.
Alkermes Plc
Aphios Corporation
Aradigm Corporation
Arbutus Biopharma Corporation
Arena Pharmaceuticals, Inc.
Astellas Pharma Inc.
Astraea Therapeutics, LLC
AstraZeneca Plc
BioDelivery Sciences International, Inc.
Bionex Pharmaceuticals LLC
Bioprojet SCR
C4X Discovery Limited
Camurus AB
Catalyst Biosciences, Inc.
Celtic Pharmaceutical Holdings L.P.
Cerecor Inc.
CoMentis, Inc.
Curemark, LLC
Eli Lilly and Company
Embera NeuroTherapeutics, Inc.
Ethypharm S.A.
Euthymics Bioscience, Inc.
Foresee Pharmaceuticals, LLC
FORUM Pharmaceuticals Inc.
Grunenthal GmbH
H. Lundbeck A/S
Heptares Therapeutics Limited
Heron Therapeutics, Inc.
Immunovaccine, Inc.
Indivior Plc
INSYS Therapeutics, Inc.
InterveXion Therapeutics LLC
Invion Limited
Johnson & Johnson
Kyorin Pharmaceutical Co., Ltd.
Lightlake Therapeutics Inc.
Lohocla Research Corporation
MAKScientific, LLC
Marinus Pharmaceuticals, Inc.
NAL Pharmaceuticals Ltd.
Neurocrine Biosciences, Inc.
Omeros Corporation
P2D Bioscience
Pfizer Inc.
Relmada Therapeutics, Inc.
Rottapharm SpA
Royalty Pharma
RTI International
Saniona AB
Selecta Biosciences, Inc.
SK Biopharmaceuticals Co., Ltd.
Stada Arzneimittel AG
Teva Pharmaceutical Industries Limited
Titan Pharmaceuticals, Inc.
Tonix Pharmaceuticals Holding Corp.
VM Discovery, Inc.
XenoPort, Inc.
Zynerba Pharmaceuticals, Inc.
Addiction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
(disulfiram + selegiline) - Drug Profile
(oxazepam + metyrapone) - Drug Profile
(samidorphan l-malate + buprenorphine hydrochloride) - Drug Profile
18-MC - DRUG PROFILE
2E-2 - DRUG PROFILE
4P-003 - DRUG PROFILE
4P-007 - DRUG PROFILE
4P-008 - DRUG PROFILE
A-705253 - Drug Profile
ABT-436 - Drug Profile
ADX-71441 - Drug Profile
ADX-71743 - Drug Profile
ADX-88178 - Drug Profile
AEF-0117 - Drug Profile
AM-6527 - Drug Profile
amitifadine - Drug Profile
Anatabine - Drug Profile
arbaclofen placarbil - Drug Profile
ASP-2905 - Drug Profile
AT-076 - Drug Profile
AT-089 - Drug Profile
AT-1001 - Drug Profile
AT-212 - Drug Profile
baclofen - Drug Profile
BP-1.4979 - Drug Profile
Buprenorphine Hemiadipate Hydrochloride - Drug Profile
buprenorphine hydrochloride - Drug Profile
buprenorphine hydrochloride - Drug Profile
buprenorphine hydrochloride - Drug Profile
buprenorphine hydrochloride depot - Drug Profile
buprenorphine hydrochloride ER - Drug Profile
buprenorphine hydrochloride long acting - Drug Profile
buprenorphine hydrochloride SR - Drug Profile
cannabidiol - Drug Profile
Cannabidiol - Drug Profile
cannabidiol - Drug Profile
carisbamate - Drug Profile
CERC-501 - Drug Profile
Ch-mAb7F9 - Drug Profile
CM-1212 - Drug Profile
Conjugate Vaccine for Methamphetamine Abuse - Drug Profile
CR-5542 Series - Drug Profile
dronabinol - Drug Profile
dronabinol - Drug Profile
Drug for Dependence - Drug Profile
Drug to Inhibit Triple Reuptake for Alcohol Dependence - Drug Profile
Drugs to Inhibit FAAH for CNS Disorders - Drug Profile
Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile
encenicline hydrochloride - Drug Profile
Enzyme for Cocaine Addiction - Drug Profile
EORA-101 - Drug Profile
FP-004 - Drug Profile
FP-007 - Drug Profile
gabapentin enacarbil XR - Drug Profile
ganaxolone - Drug Profile
Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse - Drug Profile
GET-73 - Drug Profile
GTS-21 - Drug Profile
ibudilast - Drug Profile
JDTic - Drug Profile
JNJ-39393406 - Drug Profile
JNJ-5234801 - Drug Profile
JQ-1 - Drug Profile
lofexidine hydrochloride - Drug Profile
lorcaserin hydrochloride - Drug Profile
LT-22 - Drug Profile
MC-100093 - Drug Profile
N-S2359 - Drug Profile
nadolol - Drug Profile
nalmefene - Drug Profile
naltrexone hydrochloride - Drug Profile
naltrexone hydrochloride - Drug Profile
naltrexone hydrochloride - Drug Profile
NFL-101 - Drug Profile
NIC7-DT - Drug Profile
nicotine - Drug Profile
nicotine - Drug Profile
nicotine - Drug Profile
Nicotine Vaccine - Drug Profile
Noribogaine - Drug Profile
odelepran hydrochloride - Drug Profile
OMS-405 - Drug Profile
OMS-527 - Drug Profile
ondansetron hydrochloride - Drug Profile
PF-04457845 - Drug Profile
PF-05402536 - Drug Profile
PF-06413367 - Drug Profile
PF-5006739 - Drug Profile
phantasmidine - Drug Profile
RBP-8000 - Drug Profile
Recombinant Enzyme for Cocaine Abuse - Drug Profile
RO-656570 - Drug Profile
samidorphan l-malate - Drug Profile
saracatinib difumarate - Drug Profile
SEL-068 - Drug Profile
Small Molecule for Drug Addiction - Drug Profile
Small Molecule for Smoking Cessation and Appetite Suppression - Drug Profile
Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile
Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction - Drug Profile
Small Molecule to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile
Small Molecule to Antagonize Dopamine D1, D2 and D3 Receptors for Cocaine Use Disorder - Drug Profile
Small Molecule to Antagonize Ghrelin for Alcoholism - Drug Profile
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction - Drug Profile
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS - Drug Profile
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
Small Molecules to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile
Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile
Small Molecules to Agonize NTR1 for Psychiatric Disorders and Addiction - Drug Profile
Small Molecules to Antagonize CHRNA3 and CHRNB4 for Smoking Cessation - Drug Profile
Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile
Small Molecules to Block VMAT2 for Methamphetamine Addiction - Drug Profile
Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile
Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
Small Molecules to Inhibit Kappa Opioid Receptor for CNS - Drug Profile
Small Molecules to Target 5HT2 for CNS and Metabolic Disorders - Drug Profile
Small Molecules to Target Nicotinic Acetylcholine Receptors for Drug Addiction and Drug Abuse - Drug Profile
Stem Cell Therapy to Activate DAT for Schizophrenia and Addictive Disorders - Drug Profile
Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile
Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - Drug Profile
Synthetic Peptides to Target DOR, MOR and MRP-1 for Oncology and CNS Disorders - Drug Profile
TA-CD - Drug Profile
TKM-ALDH2 - Drug Profile
TV-1380 - Drug Profile
Vaccine for Cocaine Addiction - Drug Profile
Vaccine for Drug Abuse - Drug Profile
Vaccine for Methamphetamine Addiction - Drug Profile
Vaccine for Nicotine Addiction - Drug Profile
Vaccine for Nicotine Addiction - Drug Profile
Vaccine for Opium Addiction - Drug Profile
verucerfont - Drug Profile
VMD-2202 - Drug Profile
VU-0463841 - Drug Profile
Addiction - Recent Pipeline Updates
Addiction - Dormant Projects
Addiction - Discontinued Products
Addiction - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Addiction, H2 2015
Number of Products under Development for Addiction - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Addiction - Pipeline by AbbVie Inc., H2 2015
Addiction - Pipeline by Addex Therapeutics Ltd, H2 2015
Addiction - Pipeline by Adial Pharmaceuticals, LLC, H2 2015
Addiction - Pipeline by Aelis Farma S.A.S., H2 2015
Addiction - Pipeline by Alkermes Plc, H2 2015
Addiction - Pipeline by Aphios Corporation, H2 2015
Addiction - Pipeline by Aradigm Corporation, H2 2015
Addiction - Pipeline by Arbutus Biopharma Corporation, H2 2015
Addiction - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
Addiction - Pipeline by Astellas Pharma Inc., H2 2015
Addiction - Pipeline by Astraea Therapeutics, LLC, H2 2015
Addiction - Pipeline by AstraZeneca Plc, H2 2015
Addiction - Pipeline by BioDelivery Sciences International, Inc., H2 2015
Addiction - Pipeline by Bionex Pharmaceuticals LLC, H2 2015
Addiction - Pipeline by Bioprojet SCR, H2 2015
Addiction - Pipeline by C4X Discovery Limited, H2 2015
Addiction - Pipeline by Camurus AB, H2 2015
Addiction - Pipeline by Catalyst Biosciences, Inc., H2 2015
Addiction - Pipeline by Celtic Pharmaceutical Holdings L.P., H2 2015
Addiction - Pipeline by Cerecor Inc., H2 2015
Addiction - Pipeline by CoMentis, Inc., H2 2015
Addiction - Pipeline by Curemark, LLC, H2 2015
Addiction - Pipeline by Eli Lilly and Company, H2 2015
Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H2 2015
Addiction - Pipeline by Ethypharm S.A., H2 2015
Addiction - Pipeline by Euthymics Bioscience, Inc., H2 2015
Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015
Addiction - Pipeline by FORUM Pharmaceuticals Inc., H2 2015
Addiction - Pipeline by Grunenthal GmbH, H2 2015
Addiction - Pipeline by H. Lundbeck A/S, H2 2015
Addiction - Pipeline by Heptares Therapeutics Limited, H2 2015
Addiction - Pipeline by Heron Therapeutics, Inc., H2 2015
Addiction - Pipeline by Immunovaccine, Inc., H2 2015
Addiction - Pipeline by Indivior Plc, H2 2015
Addiction - Pipeline by INSYS Therapeutics, Inc., H2 2015
Addiction - Pipeline by InterveXion Therapeutics LLC, H2 2015
Addiction - Pipeline by Invion Limited, H2 2015
Addiction - Pipeline by Johnson & Johnson, H2 2015
Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
Addiction - Pipeline by Lightlake Therapeutics Inc., H2 2015
Addiction - Pipeline by Lohocla Research Corporation, H2 2015
Addiction - Pipeline by MAKScientific, LLC, H2 2015
Addiction - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015
Addiction - Pipeline by NAL Pharmaceuticals Ltd., H2 2015
Addiction - Pipeline by Neurocrine Biosciences, Inc., H2 2015
Addiction - Pipeline by Omeros Corporation, H2 2015
Addiction - Pipeline by P2D Bioscience, H2 2015
Addiction - Pipeline by Pfizer Inc., H2 2015
Addiction - Pipeline by Relmada Therapeutics, Inc., H2 2015
Addiction - Pipeline by Rottapharm SpA, H2 2015
Addiction - Pipeline by Royalty Pharma, H2 2015
Addiction - Pipeline by RTI International, H2 2015
Addiction - Pipeline by Saniona AB, H2 2015
Addiction - Pipeline by Selecta Biosciences, Inc., H2 2015
Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015
Addiction - Pipeline by Stada Arzneimittel AG, H2 2015
Addiction - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Addiction - Pipeline by Titan Pharmaceuticals, Inc., H2 2015
Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2015
Addiction - Pipeline by VM Discovery, Inc., H2 2015
Addiction - Pipeline by XenoPort, Inc., H2 2015
Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Addiction Therapeutics - Recent Pipeline Updates, H2 2015
Addiction - Dormant Projects, H2 2015
Addiction - Dormant Projects (Contd..1), H2 2015
Addiction - Dormant Projects (Contd..2), H2 2015
Addiction - Dormant Projects (Contd..3), H2 2015
Addiction - Dormant Projects (Contd..4), H2 2015
Addiction - Dormant Projects (Contd..5), H2 2015
Addiction - Dormant Projects (Contd..6), H2 2015
Addiction - Dormant Projects (Contd..7), H2 2015
Addiction - Dormant Projects (Contd..8), H2 2015
Addiction - Dormant Projects (Contd..9), H2 2015
Addiction - Dormant Projects (Contd..10), H2 2015
Addiction - Dormant Projects (Contd..11), H2 2015
Addiction - Discontinued Products, H2 2015
Addiction - Discontinued Products (Contd..1), H2 2015

LIST OF FIGURES

Number of Products under Development for Addiction, H2 2015
Number of Products under Development for Addiction - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

AbbVie Inc.
Addex Therapeutics Ltd
Adial Pharmaceuticals, LLC
Aelis Farma S.A.S.
Alkermes Plc
Aphios Corporation
Aradigm Corporation
Arbutus Biopharma Corporation
Arena Pharmaceuticals, Inc.
Astellas Pharma Inc.
Astraea Therapeutics, LLC
AstraZeneca Plc
BioDelivery Sciences International, Inc.
Bionex Pharmaceuticals LLC
Bioprojet SCR
C4X Discovery Limited
Camurus AB
Catalyst Biosciences, Inc.
Celtic Pharmaceutical Holdings L.P.
Cerecor Inc.
CoMentis, Inc.
Curemark, LLC
Eli Lilly and Company
Embera NeuroTherapeutics, Inc.
Ethypharm S.A.
Euthymics Bioscience, Inc.
Foresee Pharmaceuticals, LLC
FORUM Pharmaceuticals Inc.
Grunenthal GmbH
H. Lundbeck A/S
Heptares Therapeutics Limited
Heron Therapeutics, Inc.
Immunovaccine, Inc.
Indivior Plc
INSYS Therapeutics, Inc.
InterveXion Therapeutics LLC
Invion Limited
Johnson & Johnson
Kyorin Pharmaceutical Co., Ltd.
Lightlake Therapeutics Inc.
Lohocla Research Corporation
MAKScientific, LLC
Marinus Pharmaceuticals, Inc.
NAL Pharmaceuticals Ltd.
Neurocrine Biosciences, Inc.
Omeros Corporation
P2D Bioscience
Pfizer Inc.
Relmada Therapeutics, Inc.
Rottapharm SpA
Royalty Pharma
RTI International
Saniona AB
Selecta Biosciences, Inc.
SK Biopharmaceuticals Co., Ltd.
Stada Arzneimittel AG
Teva Pharmaceutical Industries Limited
Titan Pharmaceuticals, Inc.
Tonix Pharmaceuticals Holding Corp.
VM Discovery, Inc.
XenoPort, Inc.
Zynerba Pharmaceuticals, Inc.
Skip to top


Alcohol Addiction - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 138 pages

Ask Your Question

Addiction - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: